Monday, April 30, 2018
I have this fear
Hallucination?
Sunday, April 29, 2018
Depressed? (part 2)
I think I'll go water my money tree. That will cheer me up. I love seeing my tree thrive. Its got six babies sprouting!
Saturday, April 28, 2018
I Don't DO Anything! (Depressed Part 1)
Thursday, April 26, 2018
New lamictal safety warning
Lamictal (lamotrigine): Drug Safety Communication - Serious Immune System Reaction
SHARE
TWEET
MORE SHARING OPTIONS
[Posted 04/25/2018]
AUDIENCE: Health Professional, Patient, Pharmacy
ISSUE: The FDA is warning that the medicine Lamictal (lamotrigine) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body’s infection-fighting immune system. This can cause severe inflammation throughout the body and lead to hospitalization and death, especially if the reaction is not diagnosed and treated quickly. As a result, we are requiring a new warning about this risk be added to the prescribing information in the lamotrigine drug labels.
BACKGROUND: The immune system reaction, called hemophagocytic lymphohistiocytosis (HLH), causes an uncontrolled response by the immune system. HLH typically presents as a persistent fever, usually greater than 101°F, and it can lead to severe problems with blood cells and organs throughout the body such as the liver, kidneys, and lungs.
Lamotrigine is used alone or with other medicines to treat seizures in patients two years and older. It may also be used as maintenance treatment in patients with bipolar disorder to help delay the occurrence of mood episodes such as depression, mania, or hypomania. Stopping lamotrigine without first talking to a prescriber can lead to uncontrolled seizures, or new or worsening mental health problems. Lamotrigine has been approved and on the market for 24 years, and is available under the brand name Lamictal and as generics.
RECOMMENDATION: Healthcare professionals should be aware that prompt recognition and early treatment is important for improving HLH outcomes and decreasing mortality. Diagnosis is often complicated because early signs and symptoms such as fever and rash are not specific. HLH may also be confused with other serious immune-related adverse reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
Evaluate patients who develop fever or rash promptly, and discontinue lamotrigine if HLH or another serious immune-related adverse reaction is suspected and an alternative etiology for the signs and symptoms cannot be established. Advise patients to seek immediate medical attention if they experience symptoms of HLH during lamotrigine treatment. A diagnosis of HLH can be established if a patient has at least five of the following eight signs or symptoms:
fever and rash
enlarged spleen
cytopenias
elevated levels of triglycerides or low blood levels of fibrinogen
high levels of blood ferritin
hemophagocytosis identified through bone marrow, spleen, or lymph node biopsy
decreased or absent Natural Killer (NK) Cell activity
elevated blood levels of CD25 showing prolonged immune cell activation
Patients or their caregivers should contact their health care professionals right away if they experience any symptom of HLH while taking lamotrigine. HLH can occur within days to weeks after starting treatment. A physical examination and specific laboratory blood tests and other evaluations are used to diagnose HLH. Signs and symptoms of HLH include but are not limited to:
fever
enlarged liver; symptoms may include pain, tenderness, or unusual swelling over the liver area in the upper right belly
swollen lymph nodes
skin rashes
yellow skin or eyes
unusual bleeding
nervous system problems, including seizures, trouble walking, difficulty seeing, or other visual disturbances
Read the patient Medication Guide, which explains the benefits and risks of lamotrigine, every time you get a new prescription because the information may change. Do not stop taking lamotrigine without talking to your health care professional first as doing so can cause serious problems.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
Complete and submit the report Online: www.fda.gov/MedWatch/report
Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
[04/25/2018 - Drug Safety Communication - FDA]
More in Safe
Tuesday, April 24, 2018
Blank
Saturday, April 21, 2018
Radio 2 - God?
I went to ask my son about his radio. It was indeed a radio. But it is tuned to a jazz music station and again its not even Sunday.
Sunday, April 15, 2018
Caring for his Wounds
I worry so much when these types of things happen and also because he doesnt listen to me. I try not to worry but I do. For everything. I try my DBT techniques.
Then my mind plays out all the bad things that could happen and they are 100% real. Even the emergency responders are there trying to find me while taking his vitals and caring for his wounds.
Tuesday, April 10, 2018
Bipolar & Math
Very much my math life throughout high school and college!
Mathematics deficits in adolescents with bipolar I disorder.
Lagace DC, et al. Am J Psychiatry. 2003.
Show full citation
Abstract
OBJECTIVE: This study examined mathematical ability in adolescents with bipolar I disorder, compared to adolescents with major depressive disorder and psychiatrically healthy comparison subjects.
METHOD: Participants (N=119) included adolescents in remission from bipolar disorder (N=44) or major depressive disorder (N=30), as well as comparison subjects (N=45) with no psychiatric history. Participants were assessed with the following measures: the Wide-Range Achievement Test, Revised 2 (WRAT-R2), Peabody Individual Achievement Test, Bay Area Functional Performance Evaluation Task-Oriented Assessment (functional mathematics subtest), Test of Nonverbal Intellegence-2, and a self-report of mathematics performance.
RESULTS: WRAT-R2 and Peabody Individual Achievement Test scores for spelling, mathematics, and reading revealed that adolescents with bipolar disorder had significantly lower achievement in mathematics, compared to subjects with major depressive disorder and comparison subjects. Results for the Test of Nonverbal Intellegence-2 were not significantly different between groups. Adolescents with bipolar disorder took significantly longer to complete the Bay Area Functional Performance Evaluation mathematics task. Significantly fewer adolescents with bipolar disorder (9%) reported above-average mathematics performance, compared with the other groups.
CONCLUSIONS: Adolescents with remitted bipolar disorder have a specific profile of mathematics difficulties that differentiates them from both adolescents with unipolar depression and psychiatrically healthy comparison subjects. These mathematics deficits may not derive simply from more global deficits in nonverbal intelligence or executive functioning, but may be associated with neuroanatomical abnormalities that result in cognitive deficits, including a slowed response time. These deficits suggest the need for specialized assessment of mathematics as part of a comprehensive clinical follow-up treatment plan.
PMID 12505807 [Indexed for MEDLINE]